Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Platform Evaluated for Yeast Infected Blood

By LabMedica International staff writers
Posted on 12 Mar 2012
A polymerase chain reaction (PCR) protocol has been optimized that will detect low numbers of yeasts in small volumes of simulated and clinical specimens.

An innovative microfluidic real-time PCR platform was evaluated for the diagnosis of invasive candidiasis and has the potential for full automation and rapid turnaround. More...


Scientists at Duke University Medical Center (Durham, NC, USA) selected samples from patients with positive blood cultures for species of Candida as well as many blood culture-negative controls. Of particular interest were 16 banked blood specimens suspected to harbor C. albicans DNA for comparative testing on conventional and microfluidic real-time PCR platforms. Each of the 16 PCR-tested blood specimens was collected within 24 hours of a specimen from the same patient that later became culture-positive for C. albicans.

Eleven and nine of 16 specimens from individual patients with culture-proven candidemia tested positive for C. albicans DNA by conventional and microfluidic real-time PCR, respectively, for a combined sensitivity of 94%. Using simulated specimens, the investigators optimized the extraction protocol to detect five colony-forming units (CFU) of C. albicans in 500 µL blood; however, testing low CFU in small blood volumes confirmed this procedure to be stochastic. This problem could be ameliorated by sampling at least 1.0 mL blood and/or performing multiple tests.

The digital microfluidic platform for real-time PCR, pioneered by Advanced Liquid Logic, Inc. (Research Triangle Park, NC, USA), has the potential to revolutionize the diagnosis of infectious diseases by offering rapid, automated, economical, and point-of-care detection of pathogenic DNA in clinical samples. The authors concluded that the ideal diagnostic PCR test should be minimally invasive, specific, and sensitive, provide early detection, and amenable to frequent testing. The assay should be effective with minimal sample sizes, and predictive of infection in the target population. It should allow quantification, identification of multiple pathogens, have a low cost, and not require special expertise to perform. They believe that the digital microfluidic real-time PCR platform is on track to satisfy all of these criteria.

Related Links:

Duke University Medical Center
Advanced Liquid Logic



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.